OR WAIT null SECS
PCI Pharma Services is investing $100 million in manufacturing capabilities and capacity expansion to its Bedford, NH facility.
PCI Pharma Services announced an expansion of capabilities and capacities to its manufacturing facility in Bedford on May 10, 2022. The company is investing $100 million into the facility’s aseptic liquid fill-finish and sterile lyophilization technology.
According to a company press release, the planned expansion consists of a 50,000 ft.² facility that will contain an aseptic fill-finish line with a fully isolated containment system. It will also have twin lyophilizers with auto-loading and unloading systems that can complete 400 vials per minute on a sterile fill-finish line.
“We are excited to introduce clients to our newest facility, which is part of our broader strategy to provide integrated end-to-end drug development, manufacturing, and packaging capabilities,” said Salim Haffar, CEO, PCI Pharma Services. “Our investment in these facilities will ensure that PCI continues to leverage new capabilities in complex formulations, aseptic fill-finish, and lyophilization to meet the needs of our global clients, particularly as biologics continue their strong growth trajectory.”
The Bedford facility, which was obtained in the acquisition of Lyophilization Services of New England in Dec. 2021, is dedicated to high-volume lyophilization, liquid filling, and multi-product handling from one format to another. This announcement follows the company’s construction of the New England Clinical Center of Excellence in Bridgewater, Mass., as well as expansions to their sites in Berlin, San Diego, Rockford, Ill., and Melbourne, Australia.
Source: PCI Pharma Services